These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

485 related articles for article (PubMed ID: 35269543)

  • 1. Comprehensive Research on Past and Future Therapeutic Strategies Devoted to Treatment of Amyotrophic Lateral Sclerosis.
    Sever B; Ciftci H; DeMirci H; Sever H; Ocak F; Yulug B; Tateishi H; Tateishi T; Otsuka M; Fujita M; Başak AN
    Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs.
    Jaiswal MK
    Med Res Rev; 2019 Mar; 39(2):733-748. PubMed ID: 30101496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Plant-Derived Compounds on Amyotrophic Lateral Sclerosis.
    de Oliveira LMG; Carreira RB; de Oliveira JVR; do Nascimento RP; Dos Santos Souza C; Trias E; da Silva VDA; Costa SL
    Neurotox Res; 2023 Jun; 41(3):288-309. PubMed ID: 36800114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current therapy in amyotrophic lateral sclerosis (ALS): A review on past and future therapeutic strategies.
    Wei Y; Zhong S; Yang H; Wang X; Lv B; Bian Y; Pei Y; Xu C; Zhao Q; Wu Y; Luo D; Wang F; Sun H; Chen Y
    Eur J Med Chem; 2024 Jun; 272():116496. PubMed ID: 38759454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A perspective on therapies for amyotrophic lateral sclerosis: can disease progression be curbed?
    Xu X; Shen D; Gao Y; Zhou Q; Ni Y; Meng H; Shi H; Le W; Chen S; Chen S
    Transl Neurodegener; 2021 Aug; 10(1):29. PubMed ID: 34372914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two Decades-Long Journey from Riluzole to Edaravone: Revisiting the Clinical Pharmacokinetics of the Only Two Amyotrophic Lateral Sclerosis Therapeutics.
    Dash RP; Babu RJ; Srinivas NR
    Clin Pharmacokinet; 2018 Nov; 57(11):1385-1398. PubMed ID: 29682695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug discovery and amyotrophic lateral sclerosis: Emerging challenges and therapeutic opportunities.
    Soares P; Silva C; Chavarria D; Silva FSG; Oliveira PJ; Borges F
    Ageing Res Rev; 2023 Jan; 83():101790. PubMed ID: 36402404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential therapeutic drugs and methods for the treatment of amyotrophic lateral sclerosis.
    Yacila G; Sari Y
    Curr Med Chem; 2014; 21(31):3583-93. PubMed ID: 24934355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Edaravone for the treatment of amyotrophic lateral sclerosis.
    Yoshino H
    Expert Rev Neurother; 2019 Mar; 19(3):185-193. PubMed ID: 30810406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Edaravone activates the GDNF/RET neurotrophic signaling pathway and protects mRNA-induced motor neurons from iPS cells.
    Li Q; Feng Y; Xue Y; Zhan X; Fu Y; Gui G; Zhou W; Richard JP; Taga A; Li P; Mao X; Maragakis NJ; Ying M
    Mol Neurodegener; 2022 Jan; 17(1):8. PubMed ID: 35012575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amyotrophic Lateral Sclerosis: An Update for 2018.
    Oskarsson B; Gendron TF; Staff NP
    Mayo Clin Proc; 2018 Nov; 93(11):1617-1628. PubMed ID: 30401437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Masitinib: The promising actor in the next season of the Amyotrophic Lateral Sclerosis treatment series.
    Ketabforoush AHME; Chegini R; Barati S; Tahmasebi F; Moghisseh B; Joghataei MT; Faghihi F; Azedi F
    Biomed Pharmacother; 2023 Apr; 160():114378. PubMed ID: 36774721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disease-modifying treatment of amyotrophic lateral sclerosis.
    Schultz J
    Am J Manag Care; 2018 Aug; 24(15 Suppl):S327-S335. PubMed ID: 30207671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disease-modifying therapies in amyotrophic lateral sclerosis.
    Chiò A; Mazzini L; Mora G
    Neuropharmacology; 2020 May; 167():107986. PubMed ID: 32062193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging Drugs for the Treatment of Amyotrophic Lateral Sclerosis: A Focus on Recent Phase 2 Trials.
    Barp A; Gerardi F; Lizio A; Sansone VA; Lunetta C
    Expert Opin Emerg Drugs; 2020 Jun; 25(2):145-164. PubMed ID: 32456491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Roots to start research in amyotrophic lateral sclerosis: molecular pathways and novel therapeutics for future.
    Harikrishnareddy D; Misra S; Upadhyay S; Modi M; Medhi B
    Rev Neurosci; 2015; 26(2):161-81. PubMed ID: 25720096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic progress in amyotrophic lateral sclerosis-beginning to learning.
    Kumar V; Islam A; Hassan MI; Ahmad F
    Eur J Med Chem; 2016 Oct; 121():903-917. PubMed ID: 27372371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New Adamantane-Containing Edaravone Conjugates as Potential Neuroprotective Agents for ALS Treatments.
    Lapshina MA; Shevtsova EF; Grigoriev VV; Aksinenko AY; Ustyugov AA; Steinberg DA; Maleev GV; Dubrovskaya ES; Goreva TV; Epishina TA; Zamoyski VL; Makhaeva GF; Fisenko VP; Veselov IM; Vinogradova DV; Bachurin SO
    Molecules; 2023 Nov; 28(22):. PubMed ID: 38005288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Edaravone: a new hope for deadly amyotrophic lateral sclerosis.
    Bhandari R; Kuhad A; Kuhad A
    Drugs Today (Barc); 2018 Jun; 54(6):349-360. PubMed ID: 29998226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small molecules targeting different cellular pathologies for the treatment of amyotrophic lateral sclerosis.
    Elmansy MF; Reidl CT; Rahaman M; Özdinler PH; Silverman RB
    Med Res Rev; 2023 Nov; 43(6):2260-2302. PubMed ID: 37243319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.